Animal models of autoimmune hepatitis

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 4, 2010, Pages 429-443

  Czaja, Albert J ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

genetic engineering; humanization; models; preconditioning; transgenic

Indexed keywords

ADENOVIRUS VECTOR; CORTICOSTEROID; CYTOCHROME P450 2D6; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; DISEASE ACTIVITY; EXPERIMENTAL MODEL; GENE INACTIVATION; GENETIC ENGINEERING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INBRED STRAIN; LIVER FIBROSIS; LYMPHOCYTIC INFILTRATION; NATURAL KILLER T CELL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; VACCINATION;

ANIMALS; ANTIGENS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC ENGINEERING; GENETIC VECTORS; HEPATITIS, AUTOIMMUNE; HUMANS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; VACCINATION;

EID: 77955257434     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.42     Document Type: Review

References (184)

1. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin. Liver Dis. 6, 727-737 (2002).
2. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev. Gastroenterol. Hepatol. 1, 113-128 (2007).
3. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin. Immunopathol. 31, 421-435 (2009).
4. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 8, 505-513 (2002).
5. Czaja AJ. Emerging opportunities for site-specifc molecular and cellular interventions in autoimmune hepatitis. Dig. Dis. Sci. DOI: 10.1007/s10620-009- 1122-1128 (2010) (Epub ahead of print).
6. Lohse AW. Experimental models of autoimmune hepatitis. Semin. Liver Dis. 11, 241-247 (1991).
7. Peters MG. Animal models of autoimmune liver disease. Immunol. Cell. Biol. 80, 113-116 (2002).
8. Jaeckel E. Animal models of autoimmune hepatitis. Semin. Liver Dis. 22, 325-338 (2002).
9. Howell CD. Animal models of autoimmunity. Clin. Liver Dis. 6, 775-783 (2002).
10. Christen U, Holdener M, Hintermann E. Animal models for autoimmune hepatitis. Autoimmun. Rev. 6, 306-311 (2007).
11. Christen U, Hintermann E, Jaeckel E. New animal models for autoimmune hepatitis. Semin. Liver Dis. 29, 262-272 (2009).
12. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223-243 (1997).
13. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33, 99-103 (1998).
14. Werner M, Prytz H, Ohlsson B et al Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand. J. Gastroenterol. 43, 1232-1240 (2008).
15. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med. 40, 159-185 (1971).
16. Soloway RD, Summerskill WH, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63, 820-833 (1972).
17. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1, 735-737 (1973).
18. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 78, 518-523 (1980).
19. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3, 685-689 (1983).
20. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35, 890-897 (2002).
21. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 8 7, 1222-1227 (1984).
22. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110, 848-857 (1996).
23. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 27, 507-515 (2007).
24. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am. J. Gastroenterol. 103, 1944-1951 (2008).
25. Yeoman AD, Al-Chalabi T, Karani JB et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 48, 863-870 (2008).
26. Gregorio GV, Portmann B, Reid F et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25, 541-547 (1997).
27. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43, 532-538 (2006).
28. Czaja AJ. Diffcult treatment decisions in autoimmune hepatitis. World J. Gastroenterol. 16, 934-947 (2010).
29. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol. 3, 269-291 (2009).
30. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol. Dietol. 51, 313-333 (2005).
31. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J. Gastroenterol. 15, 2314-2328 (2009).
32. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin. Liver Dis. 29, 315-330 (2009).
33. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N. Engl. J. Med. 341, 2068-2074 (1999).
34. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 21, 225-232 (2001).
35. Bogdanos DP, Lenzi M, Okamoto M et al Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int. J. Immunopathol. Pharmacol. 17, 83-92 (2004).
36. Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol. Immunol. 40, 1113-1120 (2004).
37. Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology 48, 1013-1015 (2008).
38. Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J. Autoimmun. 34, 38-44 (2010).
39. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J. 12, 1255-1265 (1998).
40. Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary instances in human diseases. Cell. Mol. Life Sci. 57, 542-551 (2000).
41. Kammer AR, van der Burg SH, Grabscheid B et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J. Exp. Med. 190, 169-176 (1999).
42. Vogel A, Manns MP, Strassburg CP. Autoimmunity and viruses. Clin. Liver Dis. 6, 739-753 (2002).
43. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol. Rev. 174, 250-259 (2000).
44. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig. Dis. Sci. 47, 2139-2150 (2002).
45. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 6, 379-388 (2008).
46. Strettell MD, Donaldson PT, Thomson LJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 112, 2028-2035 (1997).
47. Czaja AJ, Strettell MD, Thomson LJ et al Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25, 317-323 (1997).
48. Vazquez-Garcia MN, Alaez C, Olivo A et al MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J. Hepatol. 28, 985-990 (1998).
49. Seki T, Ota M, Furuta S et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 103, 1041-1047 (1992).
50. Yoshizawa K, Ota M, Katsuyama Y et al Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J. Hepatol. 42, 578-584 (2005).
51. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J. Gastroenterol. Hepatol. 18, 63-67 (2003).
52. Pando M, Larriba J, Fernandez GC et al Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 30, 1374-1380 (1999).
53. Goldberg AC, Bittencourt PL, Mougin B et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum. Immunol. 62, 165-169 (2001).
54. Czaja AJ, Souto EO, Bittencourt PL et al Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J. Hepatol. 37, 302-308 (2002).
55. Fortes Mdel P, Machado IV, Gil G et al Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. Liver Int. 27, 1409-1416 (2007).
56. Bittencourt PL, Goldberg AC, Cancado EL et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am. J. Gastroenterol. 94, 1906-1913 (1999).
57. Ma Y, Bogdanos DP, Hussain MJ et al Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 130, 868-882 (2006).
58. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am. J. Gastroenterol 92, 2197-2200 (1997).
59. Djilali-Saiah I, Fakhfakh A, Louaf H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II infuences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J. Hepatol. 45, 844-850 (2006).
60. Lapierre P, Beland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the infuence of genetic background in disease development. J. Autoimmun. 26, 82-89 (2006).
61. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 23, 909-916 (1996).
62. Lohr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Meyer zum Buschenfelde KH. Phenotypical analysis and cytokine release of liver-infltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 14, 161-166 (1994).
63. Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig. Dis. Sci. 45, 1028-1035 (2000).
64. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specifc antibody-induced immune tolerance involves transforming growth factor-p from phagocytes digesting apoptotic T cells. Nat. Med. 14, 528-535 (2008).
65. Bayer EM, Herr W, Kanzler S et al. Transforming growth factor-p1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J. Hepatol. 28, 803-811 (1998).
66. Schramm C, Protschka M, Kohler HH et al. Impairment of TGF-p signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G525-G535 (2003).
67. + regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun. 25, 63-71 (2005).
68. +regulatory T cells in health and autoimmune hepatitis. J. Immunol. 176, 4484-4491 (2006).
69. Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: do "NK-reg cells" exist? Cell. Mol. Immunol. 3, 241-254 (2006).
70. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. 6, 1249-1253 (2006).
71. Kawamura H, Aswad F, Minagawa M, Govindarajan S, Dennert G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J. Immunol. 176, 2152-2160 (2006). (Pubitemid 43201662)
72. Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int. Rev. Immunol. 26, 95-119 (2007).
73. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 139, 58-72 (2010).
74. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and-DR4 molecules and collagen-specifc T-cell responses. Hum. Immunol. 61, 640-650 (2000).
75. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol. 104, 276-284 (2009).
76. Rutgeerts P, D'Haens G, Targan S et al Effcacy and safety of retreatment with anti-tumor necrosis factor antibody (infiximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (1999).
77. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005). (Pubitemid 41007846)
78. Nelson DR, Tu Z, Soldevila-Pico C et al Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-infammatory effect. Hepatology 38, 859-868 (2003).
79. Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 27, 1536-1543 (1998).
80. Nagler A, Pines M, Abadi U et al Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 31, 641-648 (2000).
81. Longhi MS, Meda F, Wang P et al Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 47, 581-591 (2008).
82. Kerr TA, Davidson NO. Therapeutic RNA manipulation in liver disease. Hepatology 51, 1055-1061(2010).
83. Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3, 51-62 (2003).
84. Crispe IN, Giannandrea M, Klein I, John B, Sampson B, Wuensch S. Cellular and molecular mechanisms of liver tolerance. Immunol. Rev. 213, 101-118 (2006).
85. Benseler V, McCaughan GW, Schlitt HJ, Bishop GA, Bowen DG, Bertolino P. The liver: a special case in transplantation tolerance. Semin. Liver Dis. 27, 194-213 (2007).
86. Gonzalez-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 7, 302-310 (2001).
87. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 19, 916-924 (1994).
88. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6, 1774-1780 (2006).
89. Demetris AJ, Lunz JG 3rd, Randhawa P, Wu T, Nalesnik M, Thomson AW. Monitoring of human liver and kidney allograft tolerance: a tissue/ histopathology perspective. Transpl. Int. 22, 120-141 (2009).
90. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J. Hepatol. 50, 1247-1257 (2009).
91. Wardrop RM, 3rd, Whitacre CC. Oral tolerance in the treatment of infammatory autoimmune diseases. Infamm. Res. 48, 106-119 (1999).
92. Lohse AW, Knolle PA, Bilo K et al Antigen-presenting function and B7 expression of murine sinusoidal endothelial cells and Kupffer cells. Gastroenterology 110, 1175-1181 (1996).
93. Bumgardner GL, Li J, Heininger M, Ferguson RM, Orosz CG. In vivo immunogenicity of purifed allogeneic hepatocytes in a murine hepatocyte transplant model. Transplantation 65, 47-52 (1998).
94. Howell CD, Yoder TD. Murine experimental autoimmune hepatitis: nonspecifc infammation due to adjuvant oil. Clin. Immunol. Immunopathol. 72, 76-82 (1994).
95. Hanninen A, Harrison LC. Mucosal tolerance to prevent Type 1 diabetes: can the outcome be improved in humans? Rev. Diabet. Stud. 1, 113-121 (2004).
96. Buschenfelde KH, Kossling FK, Miescher PA. Experimental chronic active hepatitis in rabbits following immunization with human liver proteins. Clin. Exp. Immunol. 11, 99-108 (1972).
97. Kuriki J, Murakami H, Kakumu S et al. Experimental autoimmune hepatitis in mice after immunization with syngeneic liver proteins together with the polysaccharide of Klebsiella pneumoniae. Gastroenterology 84, 596-603 (1983).
98. Lohse AW, Manns M, Dienes HP, Meyer zum Buschenfelde KH, Cohen IR. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 11, 24-30 (1990).
99. Watanabe Y, Kawakami H, Kawamoto H et al. Effect of neonatal thymectomy on experimental autoimmune hepatitis in mice. Clin. Exp. Immunol. 67, 105-113 (1987).
100. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184, 387-396 (1996).
101. Tilg H, Wilmer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 103, 264-274 (1992)
102. al-Wabel A, al-Janadi M, Raziuddin S. Cytokine profle of viral and autoimmune chronic active hepatitis. J. Allergy Clin. Immunol. 92, 902-908 (1993).
103. Schlaak JF, Lohr H, Gallati H, Meyer zum Buschenfelde KH, Fleischer B. Analysis of the in vitro cytokine production by liver-infltrating T cells of patients with autoimmune hepatitis. Clin. Exp. Immunol. 94, 168-173 (1993).
104. Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-a in children with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 20, 23-27 (1995).
105. Tiegs G. Experimental hepatitis and role of cytokines. Acta Gastroenterol. Belg. 60, 176-179 (1997).
106. Tiegs G. Cellular and cytokine-mediated mechanisms of infammation and its modulation in immune-mediated liver injury. Z. Gastroenterol. 45, 63-70 (2007).
107. Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon y plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111, 462-471 (1996).
108. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21, 190-198 (1995).
109. Czaja MJ, Weiner FR, Flanders KC et al In vitro and in vivo association of transforming growth factor-p 1 with hepatic fbrosis. J. Cell Biol. 108, 2477-2482 (1989).
110. + T cells. J. Immunol. 170, 4785-4792 (2003).
111. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90, 196-203 (1992).
112. Knolle PA, Gerken G, Loser E et al. Role of sinusoidal endothelial cells of the liver in concanavalin A-induced hepatic injury in mice. Hepatology 24, 824-829 (1996).
113. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl Acad. Sci. USA 97, 5498-5503 (2000).
114. Wolfer DP, Crusio WE, Lipp HP. Knockout mice: simple solutions to the problems of genetic background and fanking genes. Trends Neuro sci. 25, 336-340 (2002).
115. Austin CP, Battey JF, Bradley A et al The knockout mouse project. Nat. Genet. 36, 921-924 (2004).
116. Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-frst century. Nat. Rev. Genet. 6, 507-512 (2005).
117. Games D, Buttini M, Kobayashi D, Schenk D, Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis. 9, 133-149 (2006).
118. Jamsai D, Zaibak F, Vadolas J et al. A humanized BAC transgenic/knockout mouse model for HbE/p-thalassemia. Genomics 88, 309-315 (2006).
119. Hims MM, Shetty RS, Pickel J et al A humanized IKBKAP transgenic mouse models a tissue-specifc human splicing defect. Genomics 90, 389-396 (2007).
120. Pearson T, Greiner DL, Shultz LD. Creation of 'humanized' mice to study human immunity. Curr. Protoc. Immunol. Chapter 15, Unit 15, 21 (2008).
121. Toyonaga T, Hino O, Sugai S et al. Chronic active hepatitis in transgenic mice expressing interferon-y in the liver. Proc. Natl Acad. Sci. USA 91, 614-618 (1994).
122. Klein L, Klein T, Ruther U, Kyewski B. CD4 T cell tolerance to human C-reactive protein, an inducible serum protein, is mediated by medullary thymic epithelium. J. Exp. Med. 188, 5-16 (1998).
123. Klein L, Kyewski B. 'Promiscuous' expression of tissue antigens in the thymus: a key to T-cell tolerance and autoimmunity? J. Mol. Med. 78, 483-494 (2000).
124. Moriyama T, Guilhot S, Klopchin K et al Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 248, 361-364 (1990).
125. Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J. Immunol. 165, 2415-2422 (2000).
126. Tamaki S, Homma S, Enomoto Y et al. Autoimmune hepatic infammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12. Clin. Immunol. 117, 280-293 (2005).
127. von Herrath MG, Fujinami RS, Whitton JL. Microorganisms and autoimmunity: making the barren feld fertile? Nat. Rev. Microbiol 1, 151-157 (2003).
128. Rizzitelli A, Berthier R, Collin V, Candeias SM, Marche PN. T lymphocytes potentiate murine dendritic cells to produce IL-12. J. Immunol. 169, 4237-4245 (2002).
129. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J. Immunol. 152, 2172-2179 (1994).
130. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 95, 3183-3190 (2000).
131. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J. Immunol. 169, 4889-4896 (2002).
132. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am. J. Gastroenterol. 90, 1206-1211 (1995).
133. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 39, 1066-1074 (2004).
134. Christen U, Edelmann KH, McGavern DB et al. A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J. Clin. Invest. 114, 1290-1298 (2004).
135. Holdener M, Hintermann E, Bayer M et al Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med. 205, 1409-1422 (2008).
136. Christen U, Holdener M, Hintermann E. Cytochrome P450 2D6 as a model antigen. Dig. Dis. 28, 80-85 (2010).
137. Hardtke-Wolenski M, Jaeckel E. Mouse models for experimental autoimmune hepatitis: limits and chances. Dig. Dis. 28, 70-79 (2010).
138. + T cells in a transgenic mouse model of autoimmune hepatitis. Gastroenterology DOI: 10.1053/j.gastro. 2010.05.075 (2010) (Epub ahead of print).
139. Doherty DG, Penzotti JE, Koelle DM et al. Structural basis of specifcity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specifc and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J. Immunol. 161, 3527-3535 (1998).
140. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 25, 219-239 (2008).
141. Speeti M, Ihantola M, Westermarck E. Subclinical versus clinical hepatitis in the dobermann: evaluation of changes in blood parameters. J. Small Anim. Pract. 37, 465-470 (1996).
142. Speeti M, Eriksson J, Saari S, Westermarck E. Lesions of subclinical doberman hepatitis. Vet. Pathol. 35, 361-369 (1998).
143. Speeti M, Stahls A, Meri S, Westermarck E. Upregulation of major histocompatibility complex class II antigens in hepatocytes in Doberman hepatitis. Vet. Immunol. Immunopathol. 96, 1-12 (2003).
144. Watson PJ. Chronic hepatitis in dogs: a review of current understanding of the aetiology, progression, and treatment. Vet. J. 167, 228-241 (2004).
145. Mandigers PJ, van den Ingh TS, Spee B, Penning LC, Bode P, Rothuizen J. Chronic hepatitis in Doberman pinschers. A review. Vet. Q. 26, 98-106 (2004).
146. Fan J, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol. Ther. 99, 261-282 (2003).
147. Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH, Fleischer B. The human hepatic asialoglycoprotein receptor is a target antigen for liver-infltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. Hepatology 12, 1314-1320 (1990).
148. Poralla T, Treichel U, Lohr H, Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin. Liver Dis. 11, 215-222 (1991)
149. Meyer zum Buschenfelde KH, Treichel U, Lohr H, Fleischer B, Poralla T. Human asialoglycoprotein receptor as an autoantigen in chronic hepatitis. Immunol. Res. 10, 497-502 (1991).
150. Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin. Exp. Immunol. 121, 364-374 (2000).
151. Wies I, Brunner S, Henninger J et al. Identifcation of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355, 1510-1515 (2000).
152. Volkmann M, Martin L, Baurle A et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifcally recognizing sera from patients with autoimmune hepatitis. Hepatology 33, 591-596 (2001).
153. Gueguen P, Dalekos G, Nousbaum JB et al. Double reactivity against actin and a-actinin defnes a severe form of autoimmune hepatitis type 1. J. Clin. Immunol. 26, 495-505 (2006).
154. Renaudineau Y, Dalekos GN, Gueguen P, Zachou K, Youinou P. Anti-a-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin. Rev. Allergy Immunol. 34, 321-325 (2008).
155. Obermayer-Straub P, Manns MP. Cytochromes P450 and UDP-glucuronosyl- transferases as hepatocellular autoantigens. Baillieres Clin. Gastroenterol. 10, 501-532 (1996). (Pubitemid 26354254)
156. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 26, 1054-1066 (1997).
157. Obermayer-Straub P, Strassburg CP, Manns MP. Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases. Can. J. Gastroenterol. 14, 429-439 (2000).
158. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev. Gastroenterol. Hepatol. 1, 129-143 (2007).
159. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312, 169-172 (1996).
160. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. JAMA 264, 2660-2662 (1990).
161. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig. Dis. Sci. 38, 744-751 (1993).
162. Germano V, Picchianti Diamanti A, Baccano G et al. Autoimmune hepatitis associated with infiximab in a patient with psoriatic arthritis. Ann. Rheum. Dis. 64, 1519-1520 (2005).
163. Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch. Intern. Med. 135, 319-321 (1975).
164. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann. Clin. Biochem. 42, 402-404 (2005).
165. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann. Intern. Med. 92, 14-19 (1980).
166. Shalev O, Mosseri M, Ariel I, Stalnikowicz R. Methyldopa-induced immune hemolytic anemia and chronic active hepatitis. Arch. Intern. Med. 143, 592-593 (1983).
167. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69, 289-302 (1975).
168. Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C. Autoimmune hepatitis triggered by administration of an herbal medicine. Am. J. Gastroenterol. 92, 703-704 (1997).
169. Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 11, 575-577 (2004).
170. Veerappan GR, Mulhall BP, Holtzmuller KC. Vaccination-induced autoimmune hepatitis. Dig. Dis. Sci. 50, 212-213 (2005).
171. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin. Liver Dis. 6, 755-774 (2002).
172. Bourdi M, Gautier JC, Mircheva J et al. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specifcity of autoantibodies and inductive capacity of the drug. Mol. Pharmacol. 42, 280-285 (1992).
173. Bourdi M, Tinel M, Beaune PH, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol. 45, 1287-1295 (1994).
174. Manns MP, Griffn KJ, Quattrochi LC et al. Identifcation of cytochrome P450IA2 as a human autoantigen. Arch. Biochem. Biophys. 280, 229-232 (1990).
175. Obermayer-Straub P, Perheentupa J, Braun S et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 121, 668-677 (2001).
176. Nagamine K, Peterson P, Scott HS et al. Positional cloning of the APECED gene. Nat. Genet. 17, 393-398 (1997).
177. Doherty DG, Donaldson PT, Underhill JA et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19, 609-615 (1994).
178. Manns MP, Czaja AJ, Gorham JD et al. Diagnosis and management of autoimmune hepatitis. Hepatology 51, 2193-2213 (2010).
179. Fiocco U, Sfriso P, Oliviero F et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun. Rev. 8, 76-82 (2008).
180. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst. Rev. 4, CD007277 (2009).
181. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fbrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118, 655-660 (2000).
182. Li MC, He SH. IL-10 and its related cytokines for treatment of infammatory bowel disease. World J. Gastroenterol. 10, 620-625 (2004).
183. Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specifc immunomodulation. Curr. Opin. Pharmacol. 4, 403-407 (2004).
184. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56, 2103-2109 (2007).